Tilray Brands Inc shares surged by 16.46%, reaching a 20-day high, amid positive market conditions with the Nasdaq-100 up 1.48% and the S&P 500 up 0.92%.
The surge is attributed to President Trump's consideration of reclassifying marijuana as a Schedule III drug, which could significantly reduce tax burdens and regulatory restrictions for cannabis companies. This potential policy change has sparked optimism within the industry, with Tilray's CEO expressing increased confidence in the future of cannabis investments.
The implications of this potential reclassification could lead to a substantial increase in institutional investments in the cannabis sector, as the market anticipates a shift in regulatory support that may enhance profitability for companies like Tilray.
Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
0 Sell
Hold
Current: 8.730
Low
8.50
Averages
9.57
High
10.00
Current: 8.730
Low
8.50
Averages
9.57
High
10.00
Roth Capital
Neutral
downgrade
$20 -> $10
2026-01-20
Reason
Roth Capital
Price Target
$20 -> $10
AI Analysis
2026-01-20
downgrade
Neutral
Reason
Roth Capital lowered the firm's price target on Tilray to $10 from $20 and keeps a Neutral rating on the shares after its Q2 results. With a re-acceleration in international sales, strong Canadian adult-use performance , and an inflection at CC Pharma, Tilray looks poised to enter a period of stronger growth, though the upside for Tilray, unfortunately, will be predominantly determined by U.S. legislative outcomes, the analyst tells investors in a research note. Tilray had been on the leading edge of intoxicating hemp products, particularly among larger manufacturers, which faces potential ban on November 13, 2026, unless extended, the firm added.
Alliance Global
Aaron Grey
Neutral
downgrade
$20 -> $10
2026-01-09
Reason
Alliance Global
Aaron Grey
Price Target
$20 -> $10
2026-01-09
downgrade
Neutral
Reason
Alliance Global analyst Aaron Grey lowered the firm's price target on Tilray to $10 from $20 and keeps a Neutral rating on the shares. Tilray reported Q2 sales above the firm's and Street estimates, driven by higher distribution revenue and international sales, with EBITDA coming in slightly above the firm's Street-matching $7.9M estimate, the analyst tells investors. The firm views the quarter as in-line on a consolidated basis with some strengths offsetting some weaknesses, but remains on the sidelines as it looks for greater transparency to long-term sales and cash flow, the analyst added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TLRY
Unlock Now
Bernstein
Market Perform
maintain
$1 -> $10
2025-12-19
Reason
Bernstein
Price Target
$1 -> $10
2025-12-19
maintain
Market Perform
Reason
Bernstein raised the firm's price target on Tilray to $10 from $1 and keeps a Market Perform rating on the shares after President Trump signed an Executive Order related to cannabis. The firm says Tilray is positioned benefit from the regulatory changes. The company yesterday announced the formation of Tilray Medical USA, with the aim of drawing on its global experience in medical cannabis operations to win in the U.S., the analyst tells investors in a research note.
ATB Capital
Underperform -> Sector Perform
upgrade
$8.50
2025-12-10
Reason
ATB Capital
Price Target
$8.50
2025-12-10
upgrade
Underperform -> Sector Perform
Reason
ATB Capital upgraded Tilray to Sector Perform from Underperform with an $8.50 price target.
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
